ST PAUL, MINNESOTA — Recombinetics (, a St. Paul-based global biotechnology leader in gene editing of livestock for human therapeutic and food production applications, is pleased to announce the hiring of David Aberle as Vice President of Finance and Interim Chief Financial Officer.

“Recombinetics is pleased to welcome David Aberle  to our team,” said Ian Friendly, Recombinetics’ Chief Executive Officer. “David Aberle will help drive efficiencies in our financial and operating models to better position us for commercial expansion and our capital raise.


Aberle comes to Recombinetics with 20 years of experience in financial and strategic management including six years in the medical device industry at AGA Medical Corporation (now part of St. Jude Medical) where he served as Interim Chief Financial Officer, Corporate Controller, Treasurer and other key financial leadership roles.  His expertise includes leading implementation of financial, operational and human capital systems during times critical to a company’s success.

Aberle earned a Masters of Business Administration and a Mini Masters of Medical Technology from the University of St. Thomas.  He obtained his CPA and CTP credentials and has been involved with the Turnaround Management Association, Financial Executives International, Association for Financial Professionals and Minnesota Treasury Management Association. He also owns agricultural interests in livestock and crop farming.

As the Vice President of Finance and Interim Chief Financial Officer, Aberle is responsible for supporting ongoing capital raising and overseeing all aspects of finance; audit; accounting; tax; facilities; and information technology.

Aberle added, “I joined Recombinetics because, through gene-editing, we can expedite advances in the treatment of human diseases, improve the health of animals, and provide sustainable solutions for the world’s food supply.  In my career, I’ve seen the financial consequences of not having reliable models for the pre-clinical testing of medical devices.  Recombinetics’ biomedical swine models provide a more precise and predictable pathway for testing new medical devices and reduce the time and expense from pre-clinical trials to filing for FDA approval.”